Impact of race on asthma treatment failures in the Asthma Clinical Research Network

Michael E. Wechsler, Mario Castro, Erik Lehman, Vernon M. Chinchilli, E. Rand Sutherland, Loren Denlinger, Stephen C. Lazarus, Stephen P. Peters, Elliot Israel, Richard J. Martin, Stanley J. Szefler, Reuben Cherniack, Robert F. Lemanske, Christine A. Sorkness, Nizar Jarjour, Tim Craig, Susan J. Kunselman, Homer A. Boushey, John V. Fahy, Monica Kraft & 9 others Steven Wasserman, Joe Ramsdell, William Calhoun, Bill Ameredes, Michael Walter, Eugene Bleecker, Emily DiMango, Gene R. Pesola, Robert Smith

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Rationale: Recent studies suggest that people with asthma of different racial backgrounds may respond differently to various therapies. Objectives: To use data from well-characterized participants in prior Asthma Clinical Research Network (ACRN) trials to determine whether racial differences affected asthma treatment failures. Methods: We analyzed baseline phenotypes and treatment failure rates (worsening asthma resulting in systemic corticosteroid use, hospitalization, emergency department visit, prolonged decrease in peak expiratory flow, increase in albuterol use, or safety concerns) in subjects participating in 10ACRNtrials (1993-2003). Self-declared race was reported in each trial and treatment failure rates were stratified by race. Measurements and Main Results: A total of 1,200 unique subjects (whites = 795 [66%]; African Americans = 233 [19%]; others = 172 [14%]; mean age = 32) were included in the analyses. At baseline, African Americans had fewer asthma symptoms (P < 0.001) and less average daily rescue inhaler use (P = 0.007) than whites. There were no differences in baseline FEV 1 (% predicted); asthma quality of life; bronchial hyperreactivity; or exhaled nitric oxide concentrations. A total of 147 treatment failures were observed; a significantly higher proportion of AfricanAmericans(19.7%;n=46) experienceda treatment failure compared with whites (12.7%; n = 101) (odds ratio = 1.7; 95% confidence interval, 1.2-2.5; P = 0.007). When stratified by treatment, African Americans receiving long-acting β-agonists were twice as likely as whites to experience a treatment failure (odds ratio = 2.1; 95% confidence interval, 1.3-3.6; P = 0.004), even when used with other controller therapies. Conclusions: Despite having fewer asthma symptoms and less rescue β-agonist use, African-Americans with asthma have more treatment failures compared with whites, especially when taking long-acting β-agonists.

Original languageEnglish (US)
Pages (from-to)1247-1253
Number of pages7
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume184
Issue number11
DOIs
StatePublished - Dec 1 2011
Externally publishedYes

Fingerprint

Treatment Failure
Asthma
Research
African Americans
Odds Ratio
Confidence Intervals
Bronchial Hyperreactivity
Albuterol
Nebulizers and Vaporizers
Hospital Emergency Service
Adrenal Cortex Hormones
Nitric Oxide
Hospitalization
Therapeutics
Quality of Life
Phenotype
Safety

Keywords

  • African Americans
  • Asthma
  • Long-acting β-agonist
  • Race
  • Treatment failure

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Wechsler, M. E., Castro, M., Lehman, E., Chinchilli, V. M., Sutherland, E. R., Denlinger, L., ... Smith, R. (2011). Impact of race on asthma treatment failures in the Asthma Clinical Research Network. American Journal of Respiratory and Critical Care Medicine, 184(11), 1247-1253. https://doi.org/10.1164/rccm.201103-0514OC

Impact of race on asthma treatment failures in the Asthma Clinical Research Network. / Wechsler, Michael E.; Castro, Mario; Lehman, Erik; Chinchilli, Vernon M.; Sutherland, E. Rand; Denlinger, Loren; Lazarus, Stephen C.; Peters, Stephen P.; Israel, Elliot; Martin, Richard J.; Szefler, Stanley J.; Cherniack, Reuben; Lemanske, Robert F.; Sorkness, Christine A.; Jarjour, Nizar; Craig, Tim; Kunselman, Susan J.; Boushey, Homer A.; Fahy, John V.; Kraft, Monica; Wasserman, Steven; Ramsdell, Joe; Calhoun, William; Ameredes, Bill; Walter, Michael; Bleecker, Eugene; DiMango, Emily; Pesola, Gene R.; Smith, Robert.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 184, No. 11, 01.12.2011, p. 1247-1253.

Research output: Contribution to journalArticle

Wechsler, ME, Castro, M, Lehman, E, Chinchilli, VM, Sutherland, ER, Denlinger, L, Lazarus, SC, Peters, SP, Israel, E, Martin, RJ, Szefler, SJ, Cherniack, R, Lemanske, RF, Sorkness, CA, Jarjour, N, Craig, T, Kunselman, SJ, Boushey, HA, Fahy, JV, Kraft, M, Wasserman, S, Ramsdell, J, Calhoun, W, Ameredes, B, Walter, M, Bleecker, E, DiMango, E, Pesola, GR & Smith, R 2011, 'Impact of race on asthma treatment failures in the Asthma Clinical Research Network', American Journal of Respiratory and Critical Care Medicine, vol. 184, no. 11, pp. 1247-1253. https://doi.org/10.1164/rccm.201103-0514OC
Wechsler, Michael E. ; Castro, Mario ; Lehman, Erik ; Chinchilli, Vernon M. ; Sutherland, E. Rand ; Denlinger, Loren ; Lazarus, Stephen C. ; Peters, Stephen P. ; Israel, Elliot ; Martin, Richard J. ; Szefler, Stanley J. ; Cherniack, Reuben ; Lemanske, Robert F. ; Sorkness, Christine A. ; Jarjour, Nizar ; Craig, Tim ; Kunselman, Susan J. ; Boushey, Homer A. ; Fahy, John V. ; Kraft, Monica ; Wasserman, Steven ; Ramsdell, Joe ; Calhoun, William ; Ameredes, Bill ; Walter, Michael ; Bleecker, Eugene ; DiMango, Emily ; Pesola, Gene R. ; Smith, Robert. / Impact of race on asthma treatment failures in the Asthma Clinical Research Network. In: American Journal of Respiratory and Critical Care Medicine. 2011 ; Vol. 184, No. 11. pp. 1247-1253.
@article{bf46f654303f441b9ecdbc7f5b7a5338,
title = "Impact of race on asthma treatment failures in the Asthma Clinical Research Network",
abstract = "Rationale: Recent studies suggest that people with asthma of different racial backgrounds may respond differently to various therapies. Objectives: To use data from well-characterized participants in prior Asthma Clinical Research Network (ACRN) trials to determine whether racial differences affected asthma treatment failures. Methods: We analyzed baseline phenotypes and treatment failure rates (worsening asthma resulting in systemic corticosteroid use, hospitalization, emergency department visit, prolonged decrease in peak expiratory flow, increase in albuterol use, or safety concerns) in subjects participating in 10ACRNtrials (1993-2003). Self-declared race was reported in each trial and treatment failure rates were stratified by race. Measurements and Main Results: A total of 1,200 unique subjects (whites = 795 [66{\%}]; African Americans = 233 [19{\%}]; others = 172 [14{\%}]; mean age = 32) were included in the analyses. At baseline, African Americans had fewer asthma symptoms (P < 0.001) and less average daily rescue inhaler use (P = 0.007) than whites. There were no differences in baseline FEV 1 ({\%} predicted); asthma quality of life; bronchial hyperreactivity; or exhaled nitric oxide concentrations. A total of 147 treatment failures were observed; a significantly higher proportion of AfricanAmericans(19.7{\%};n=46) experienceda treatment failure compared with whites (12.7{\%}; n = 101) (odds ratio = 1.7; 95{\%} confidence interval, 1.2-2.5; P = 0.007). When stratified by treatment, African Americans receiving long-acting β-agonists were twice as likely as whites to experience a treatment failure (odds ratio = 2.1; 95{\%} confidence interval, 1.3-3.6; P = 0.004), even when used with other controller therapies. Conclusions: Despite having fewer asthma symptoms and less rescue β-agonist use, African-Americans with asthma have more treatment failures compared with whites, especially when taking long-acting β-agonists.",
keywords = "African Americans, Asthma, Long-acting β-agonist, Race, Treatment failure",
author = "Wechsler, {Michael E.} and Mario Castro and Erik Lehman and Chinchilli, {Vernon M.} and Sutherland, {E. Rand} and Loren Denlinger and Lazarus, {Stephen C.} and Peters, {Stephen P.} and Elliot Israel and Martin, {Richard J.} and Szefler, {Stanley J.} and Reuben Cherniack and Lemanske, {Robert F.} and Sorkness, {Christine A.} and Nizar Jarjour and Tim Craig and Kunselman, {Susan J.} and Boushey, {Homer A.} and Fahy, {John V.} and Monica Kraft and Steven Wasserman and Joe Ramsdell and William Calhoun and Bill Ameredes and Michael Walter and Eugene Bleecker and Emily DiMango and Pesola, {Gene R.} and Robert Smith",
year = "2011",
month = "12",
day = "1",
doi = "10.1164/rccm.201103-0514OC",
language = "English (US)",
volume = "184",
pages = "1247--1253",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "11",

}

TY - JOUR

T1 - Impact of race on asthma treatment failures in the Asthma Clinical Research Network

AU - Wechsler, Michael E.

AU - Castro, Mario

AU - Lehman, Erik

AU - Chinchilli, Vernon M.

AU - Sutherland, E. Rand

AU - Denlinger, Loren

AU - Lazarus, Stephen C.

AU - Peters, Stephen P.

AU - Israel, Elliot

AU - Martin, Richard J.

AU - Szefler, Stanley J.

AU - Cherniack, Reuben

AU - Lemanske, Robert F.

AU - Sorkness, Christine A.

AU - Jarjour, Nizar

AU - Craig, Tim

AU - Kunselman, Susan J.

AU - Boushey, Homer A.

AU - Fahy, John V.

AU - Kraft, Monica

AU - Wasserman, Steven

AU - Ramsdell, Joe

AU - Calhoun, William

AU - Ameredes, Bill

AU - Walter, Michael

AU - Bleecker, Eugene

AU - DiMango, Emily

AU - Pesola, Gene R.

AU - Smith, Robert

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Rationale: Recent studies suggest that people with asthma of different racial backgrounds may respond differently to various therapies. Objectives: To use data from well-characterized participants in prior Asthma Clinical Research Network (ACRN) trials to determine whether racial differences affected asthma treatment failures. Methods: We analyzed baseline phenotypes and treatment failure rates (worsening asthma resulting in systemic corticosteroid use, hospitalization, emergency department visit, prolonged decrease in peak expiratory flow, increase in albuterol use, or safety concerns) in subjects participating in 10ACRNtrials (1993-2003). Self-declared race was reported in each trial and treatment failure rates were stratified by race. Measurements and Main Results: A total of 1,200 unique subjects (whites = 795 [66%]; African Americans = 233 [19%]; others = 172 [14%]; mean age = 32) were included in the analyses. At baseline, African Americans had fewer asthma symptoms (P < 0.001) and less average daily rescue inhaler use (P = 0.007) than whites. There were no differences in baseline FEV 1 (% predicted); asthma quality of life; bronchial hyperreactivity; or exhaled nitric oxide concentrations. A total of 147 treatment failures were observed; a significantly higher proportion of AfricanAmericans(19.7%;n=46) experienceda treatment failure compared with whites (12.7%; n = 101) (odds ratio = 1.7; 95% confidence interval, 1.2-2.5; P = 0.007). When stratified by treatment, African Americans receiving long-acting β-agonists were twice as likely as whites to experience a treatment failure (odds ratio = 2.1; 95% confidence interval, 1.3-3.6; P = 0.004), even when used with other controller therapies. Conclusions: Despite having fewer asthma symptoms and less rescue β-agonist use, African-Americans with asthma have more treatment failures compared with whites, especially when taking long-acting β-agonists.

AB - Rationale: Recent studies suggest that people with asthma of different racial backgrounds may respond differently to various therapies. Objectives: To use data from well-characterized participants in prior Asthma Clinical Research Network (ACRN) trials to determine whether racial differences affected asthma treatment failures. Methods: We analyzed baseline phenotypes and treatment failure rates (worsening asthma resulting in systemic corticosteroid use, hospitalization, emergency department visit, prolonged decrease in peak expiratory flow, increase in albuterol use, or safety concerns) in subjects participating in 10ACRNtrials (1993-2003). Self-declared race was reported in each trial and treatment failure rates were stratified by race. Measurements and Main Results: A total of 1,200 unique subjects (whites = 795 [66%]; African Americans = 233 [19%]; others = 172 [14%]; mean age = 32) were included in the analyses. At baseline, African Americans had fewer asthma symptoms (P < 0.001) and less average daily rescue inhaler use (P = 0.007) than whites. There were no differences in baseline FEV 1 (% predicted); asthma quality of life; bronchial hyperreactivity; or exhaled nitric oxide concentrations. A total of 147 treatment failures were observed; a significantly higher proportion of AfricanAmericans(19.7%;n=46) experienceda treatment failure compared with whites (12.7%; n = 101) (odds ratio = 1.7; 95% confidence interval, 1.2-2.5; P = 0.007). When stratified by treatment, African Americans receiving long-acting β-agonists were twice as likely as whites to experience a treatment failure (odds ratio = 2.1; 95% confidence interval, 1.3-3.6; P = 0.004), even when used with other controller therapies. Conclusions: Despite having fewer asthma symptoms and less rescue β-agonist use, African-Americans with asthma have more treatment failures compared with whites, especially when taking long-acting β-agonists.

KW - African Americans

KW - Asthma

KW - Long-acting β-agonist

KW - Race

KW - Treatment failure

UR - http://www.scopus.com/inward/record.url?scp=82555196052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555196052&partnerID=8YFLogxK

U2 - 10.1164/rccm.201103-0514OC

DO - 10.1164/rccm.201103-0514OC

M3 - Article

VL - 184

SP - 1247

EP - 1253

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 11

ER -